SNMMI23
The primary endpoint of dCR at six months strongly favored 131I-apamistamab with 22% dCR versus 0% for conventional care.
Multiple regression did not define any independent predictor of response for early evaluation among the baseline parameters.
Advertisement
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.